Background and Aim: Worldwide, HCC is the cause of thousand deathsper year. The aim of this study was to test whether syndecan-1 andlaminin could serve as a non-invasive marker for detection of liverfibrosis and thereby reduce the need for liver biopsy in HCC patients.Subjects and Methods: The study included 30 patients with HCC and20 healthy subjects serving as control. Patients were staged according toliver biopsies (Metavir fibrosis staging, stage F2 n = 3, F3, n = 7; F4, n =20).Laminin and syndecan-1 was measured with an enzyme-linkedimmunosorbent assay.Results. Laminin and syndecan-1 levels were significantly higher in theF4 than F2 and F3 ,meanwhile there was no significant differencebetween F3 and F2. Laminin and syndecan-1 levels were significantlyhigher in the HCC patients than in controls. The diagnostic sensitivity oflaminin at a cutoff value of 213.3903 ng/ml was 100% and specificitywas 75%. The diagnostic sensitivity of syndecan-1 at a cutoff of 19.4487ng/dl was 100% and the specificity was 75%.Conclusion. Combination of laminin and syndecan-1 as non invasivemarkers of liver fibrosis in HCC would improve the diagnostic power ofthese markers.